Should You Buy Minerva Neurosciences Inc (NERV) Stock After it Has Gained 20.71% in a Week?

The market has been high on Minerva Neurosciences Inc (NERV) stock recently. NERV gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Minerva Neurosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NERV!

See Full NERV Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With NERV Stock Today?

Minerva Neurosciences Inc (NERV) stock has gained 8.69% while the S&P 500 has fallen -0.58% as of 11:02 AM on Monday, Feb 5. NERV is up $0.82 from the previous closing price of $9.44 on volume of 37,595 shares. Over the past year the S&P 500 is higher by 19.91% while NERV is up 245.45%. NERV lost -$4.72 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Minerva Neurosciences Inc click here.

More About Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease. Click Here to get the full Stock Report for Minerva Neurosciences Inc stock.